Photocure ASA (0IMT) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

All right. Well, good afternoon. Good morning to everyone. This is PhotoCare ASA fourth quarter and full year 2025 results. I'm Dan Schneider, President and CEO. Today with me is Eric Dahl, CFO, and Priyam Shah, our Vice President of IR. Just a reminder, the usual disclaimers are in effect for today's presentation. So I'd like to start off with the strategic priorities and initiatives of PhotoCare. Our strategic priorities guide how we execute and allocate resources across a company. At a high level, our strategy is centered around three key pillars. Strengthen the core Hexafix-SysFu business. Advance blue light cystoscopy as a definitive standard of care in bladder cancer. And third, expand our reach into a broader uro-oncology and precision diagnostic space. Taking a deeper dive in the first pillar, accelerate and expand, we need to deliver on our financial guidance for disciplined growth in revenue and EBITDA in our core business and continue generating operating leverage. We also need to drive the BLC mobile strategy for tech in the U.S., that hits the hospital markets or the hospitals who otherwise wouldn't have access to blue light cystoscopy. And in the EU, it's important we increase our penetration in our high-priority growth markets through BLC expansion and additional image quality upgrades throughout the continent, and also expand our geographic footprint, for example, most recently Spain last year, and leverage our distribution partnerships throughout the globe. In the second pillar, positioning and access, we are building the foundations for BLC as a primary precision diagnostic tool to facilitate early and appropriate use of new NMIBC therapeutics, detection, surveillance, and therapeutic monitoring. We also need to support high-depth BLC technologies t...